Cymbalta Pain Advisory Committee Could Hinge On Hepatotoxicity Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
The new indication for Lilly's SNRI would expose a much larger patient population to the risk of liver injury. The FDA reviewer and his supervisors disagree about how to handle the concern.